Selected Grants
RBC Effects on Neutrophil Activation and Phenotypes in Sickle Cell Disease
ResearchCo Investigator · Awarded by National Institutes of Health · 2024 - 2029U2C/TL1 NC KUH TRIO Administrative Core
ResearchPreceptor · Awarded by University of North Carolina - Chapel Hill · 2023 - 2028TRIO NRSA Training Core-Pre Doc Trainee
Inst. Training Prgm or CMEPreceptor · Awarded by University of North Carolina - Chapel Hill · 2023 - 2028Sickle Cell Disease Functional Assessment Validation and Exercise Pilot Intervention
ResearchMentor · Awarded by National Heart, Lung, and Blood Institute · 2023 - 2028GBT2104-133 - An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial
Clinical TrialPrincipal Investigator · Awarded by Global Blood Therapeutics, Inc. · 2023 - 2027RBC Effects on Neutrophil Activation and Phenotypes in Sickle Cell Disease
ResearchCo Investigator · Awarded by National Institutes of Health · 2024 - 2029U2C/TL1 NC KUH TRIO Administrative Core
ResearchPreceptor · Awarded by University of North Carolina - Chapel Hill · 2023 - 2028TRIO NRSA Training Core-Pre Doc Trainee
Inst. Training Prgm or CMEPreceptor · Awarded by University of North Carolina - Chapel Hill · 2023 - 2028Sickle Cell Disease Functional Assessment Validation and Exercise Pilot Intervention
ResearchMentor · Awarded by National Heart, Lung, and Blood Institute · 2023 - 2028GBT2104-133 - An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial
Clinical TrialPrincipal Investigator · Awarded by Global Blood Therapeutics, Inc. · 2023 - 2027Point of care diagnostic for sickle cell disease
ResearchCo Investigator · Awarded by National Institutes of Health · 2024 - 2027Staphylococcus aureus Cardiac Device Infections - From the Vascular Viewpoint (K23)
ResearchAdvisor · Awarded by National Institutes of Health · 2022 - 2027'Omics predictors of Sickle Cell Severity and Survival
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2024 - 2026Hematology & Transfusion Medicine (T32)
Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 1975 - 2026GBT2104-131 A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease (SCD) Experiencing Vaso-occlusive Crisis (VOCs)
Clinical TrialPrincipal Investigator · Awarded by Global Blood Therapeutics, Inc. · 2021 - 2025Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE)
Clinical TrialPrincipal Investigator · Awarded by University of Maryland, Baltimore · 2022 - 2025FORMA FT4202-Hem-301 PRAISE PTV. An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE).
Clinical TrialPrincipal Investigator · Awarded by FORMA Therapeutics, Inc. · 2021 - 2025Multi-site Clinical Laboratory Testing for SickleScan
Clinical TrialPrincipal Investigator · Awarded by BioMedomics, Inc. · 2017 - 2025A Phase II trial of topical sodium nitrite in patients with sickle cell disease and leg ulcers Cost Reimbursable
Clinical TrialPrincipal Investigator · Awarded by Food and Drug Administration · 2021 - 20244202-HEM-201 Pro00109172
Clinical TrialPrincipal Investigator · Awarded by FORMA Therapeutics, Inc. · 2022 - 2024Duke CTSA (TL1) Year 5
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2018 - 2024Randomized double-blind study of FT-4202 in sickle cell disease
Clinical TrialPrincipal Investigator · Awarded by FORMA Therapeutics, Inc. · 2019 - 2024Identifying novel clinical, genetic and proteomic risk factors for sickle cell nephropathy.
ResearchCo Investigator · Awarded by National Institutes of Health · 2021 - 2023Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE)
Clinical TrialPrincipal Investigator · Awarded by University of Pittsburgh · 2020 - 2022Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE)
Clinical TrialPrincipal Investigator · Awarded by University of Pittsburgh · 2020 - 2022AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF RIVIPANSEL (GMI-1070) IN THE TREATMENT OF ONE OR MORE VASOOCCLUSIVE CRISES IN HOSPITALIZED SUBJECTS WITH SICKLE CELL DISEASE
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2016 - 2021CSA - Pfizer 212511 B5201002 Phase 3 Randomized Multicenter Trial
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2015 - 2021Patient Preference Information: Bridging Regulatory Decisions and Clinical Practice
ResearchPhysician · Awarded by Food and Drug Administration · 2018 - 2021FORMA Therapeutics FT-4202
ResearchPrincipal Investigator · Awarded by FORMA Therapeutics, Inc. · 2019 - 2021Sharing Comprehensive 'Omics in Sickle Cell Disease Through the NHLBI TOPMed Network
ResearchPrincipal Investigator · Awarded by Doris Duke Charitable Foundation, Inc. · 2019 - 2020Transcriptomic, therapeutic and genetic investigations of sickle cell nephropathy
ResearchCo Investigator · Awarded by National Institutes of Health · 2016 - 2020Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE)
Clinical TrialPrincipal Investigator · Awarded by University of Pittsburgh · 2020 - 2020High-throughput Metabolite Profiling and Genetic Analyses to Identify Novel Predictive Biomarkers of SCD-related Complications
ResearchPrincipal Investigator · Awarded by Doris Duke Charitable Foundation · 2015 - 2020Duke-UNC Clinical Hematology and Transfusion Research Career Development Program
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2006 - 2019Use of Mobile Technology to Improve Acute Care Utilization in Sickle Cell Disease
ResearchCo Investigator · Awarded by Agency for Healthcare Research and Quality · 2015 - 2018Vanderbilt-Emory-Cornell-Duke Consortium for Global Health Fellows (VECDor)
FellowshipPrincipal Investigator · Awarded by Vanderbilt University · 2017 - 2018Thalassemia Screening in Myanmese and Lao Migrants in Thailand
FellowshipPrincipal Investigator · Awarded by Cooley's Anemia Foundation · 2017 - 2018Factor XIII and Fibrinogen: Mechanisms of Genetic Risk in SCD-Related Priapism
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2015 - 2018Improving Pain in Sickle Cell Patients With Targeted Antithrombotic Therapy
ResearchCo-Mentor · Awarded by National Institutes of Health · 2014 - 2017PFIZER B0401016
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2015 - 2017Role of RBC NO and ATP in Sickle Vasculopathy
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2012 - 2016Extension of Hematologic & Clinical Genotype-Phenotype Associations in SCD Using Exome Chip & Metabolomic Analysis
ResearchPrincipal Investigator · Awarded by Doris Duke Charitable Foundation · 2013 - 2015Instrumentation for Quantitative Phosphoproteomics and Acetylomics
EquipmentMajor User · Awarded by National Institutes of Health · 2014 - 2015Lateral Flow Hemoglobinopathies Test Development
ResearchPrincipal Investigator · Awarded by BioMedomics, Inc. · 2014 - 2014Impaired release of antiadhesive ATP from stored RBCs: a novel transfusion lesion
ResearchClinical Investigator · Awarded by National Institutes of Health · 2012 - 2014Phase II Study of Propranolol as Anti-Adhesive Therapy in SCD
ResearchMentor · Awarded by National Institutes of Health · 2009 - 2013PROPRANOLOL AS ANTI-ADHESIVE THERAPY IN SCD
Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2010 - 2012Duke/UNC Comprehensive Sickle Cell Center
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2003 - 2012Training in the Genome Sciences and the Hemoglobinopathies
Inst. Training Prgm or CMECo-Director · Awarded by National Institutes of Health · 2006 - 2012Training in the Genome Sciences and the Hemoglobinopathies
Inst. Training Prgm or CMECo-Director · Awarded by National Institutes of Health · 2006 - 2012Relationship of Depression to SCD Severity, Health Care Utilization and QoL
ResearchCo Investigator · Awarded by Agency for Healthcare Research and Quality · 2008 - 2011Pulmonary Hypertension in SCD
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2005 - 2011The Genomic Analysis of Erythrocyte microRNA in Sickle Cell Diseases
ResearchCo Investigator · Awarded by National Institutes of Health · 2008 - 2011Duke-UNC Sickle Cell Disease Clinical Research Network
ResearchPrincipal Investigator · Awarded by National Heart, Lung, and Blood Institute · 2006 - 2011Outcome Modifying Genes in Sickle Cell Diseases
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2001 - 2008Activation of Sickle Red Cell Adhesion
ResearchMentor · Awarded by National Institutes of Health · 2003 - 2007Adrenergic Receptor Variants and RBC Adhesion in SCD
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2004 - 2007Minority Invest Post-Bacc Res. Supp. - T Jackson
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2001 - 2006Factors Involved in B-CAM/LU-Mediated Adhesion
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1999 - 2003Sickle Cell Adhesion
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1997 - 2003Transfusion Medicine And Related Areas
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by National Institutes of Health · 1975 - 1999Molecular Targets Of The In Lu Gene
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1987 - 1997Molecular Targets Of The In(Lu) Gene
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1993 - 1997Molecular Targets Of The In (Lu) Gene
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1987 - 1997Transfusion Medicine And Related Areas
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1975 - 1996Transfusion Medicine And Related Areas
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by National Institutes of Health · 1975 - 1996Phosphatidylinositol-Anchored Blood Group Antigens
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1994 - 1995Erythrocyte Protein Antigens Regulated By In-Lu
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1992 - 1993Erythrocyte Protein Antigens Regulated By In(Lu)
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1991 - 1993Erythrocyte Protein Antigens Regulated By In(Lu)
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1992 - 1993Erythrocyte Blood Group Antigens Regulated By In(Lu)
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1986 - 1988Erythrocyte Blood Group Antigens Regulated By In (Lu)
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1985 - 1987External Relationships
- GLG
- Guidepoint Global
- Novartis
- Pfizer Inc.
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.